The outcomes of patients with idiopathic pulmonary fibrosis (IPF) remain unknown. Alongside the global adoption of antifibrotic therapies, there is currently relentless research for biomarkers and ...

pulmonary fibrosis can remain challenging to effectively treat. This is in part because lung cells can be driven to a profibrotic phenotype by multiple pathways that reinforce each other ...

signalling pathway inhibitor. Both are trying to improve on current standard-of-care therapies for IPF that may slow the decline of lung function, but do not stop or reverse it, and new data ...

Idiopathic pulmonary fibrosis (IPF) is a rare lung disease characterized by ... They also found genes involved in the mTOR signaling pathway, which is central in lung fibrosis, and in mucin ...

Researchers have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people worldwide.

Roughly one in five (21 percent) of idiopathic pulmonary fibrosis (IPF) deaths might be related to occupational exposures, according to research published in the March 6 issue of the U.S. Centers ...

Dr Ahmed Fahim discusses the UK Idiopathic Pulmonary Fibrosis Registry and how its findings enhance understanding and clinical management.

IPF is rapidly progressive and causes scarring in the lungs, making it difficult to breathe. Approximately 50% of patients die within three years of diagnosis, and current treatments can only slow ...